Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 14/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DHPS | P49366 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21406252 | 0.88 | LMNA (0.56) | STING1LMNA | |
| SCHEMBL23480247 | 0.84 | LMNA (0.41) | STING1LMNADHPSHDAC1HDAC3 | |
| SCHEMBL21405856 | 0.83 | STING1 (0.57) | STING1 | |
| SCHEMBL29901437 | 0.81 | STING1 (0.55) | STING1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL23461392 | 0.81 | STING1 (0.55) | STING1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL30151656 | 0.80 | BCL2L1 (0.59) | LMNADHPSHDAC1HDAC3HDAC4 | |
| SCHEMBL498133 | 0.80 | BCL2L1 (0.59) | LMNADHPSHDAC1HDAC3HDAC4 | |
| SCHEMBL11232455 | 0.80 | BCL2L1 (0.64) | STING1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL23461338 | 0.78 | STING1 (0.52) | STING1HDAC1 | |
| SCHEMBL23462094 | 0.78 | STING1 (0.52) | STING1LMNAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | STING1, IRF3, CGAS | STING1 1/4885LMNA 3201/4885DHPS 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.